Elise van Mulligen

Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study

Elise van Mulligen, Pascal H P de Jong, T. Martijn Kuijper et al. · Annals of the Rheumatic Diseases · 2019 · 64 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial

Elise van Mulligen, A. Weel, J. M. W. Hazes et al. · Annals of the Rheumatic Diseases · 2020 · 47 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14

The impact of a disease flare during tapering of DMARDs on the lives of rheumatoid arthritis patients

Elise van Mulligen, A. Weel, T. Martijn Kuijper et al. · Seminars in Arthritis and Rheumatism · 2020 · 29 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia

H.W. van Steenbergen, Frank Doornkamp, Stefano Alivernini et al. · Annals of the Rheumatic Diseases · 2025 · 24 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial

Elise van Mulligen, A. Weel, T. Martijn Kuijper et al. · Annals of the Rheumatic Diseases · 2020 · 20 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17